BioCentury

7:00 AM GMT, Apr 25, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Still Banking on the Best

Merck & Co. Inc. isn't saying why it handed betrixaban back to Portola Pharmaceuticals Inc., but the biotech still believes the oral Factor Xa inhibitor has best-in-class potential. Portola thus plans to move the compound into Phase III testing itself, but in a smaller indication than it had hoped to pursue with Merck.

Betrixaban belongs to a new wave of anticoagulants designed to block one of two individual coagulation factors: either thrombin or Factor Xa. These compounds are intended to replace warfarin, which is widely used but carries a risk of major bleeding and has complicated dosing, unpredictable kinetics and interactions with many drugs and even food.

In 2009, Merck paid $50 million up front for worldwide rights to betrixaban. The molecule had completed a Phase II trial to prevent venous thromboembolism (VTE) and was in a Phase IIb trial to prevent stroke in atrial fibrillation

Read the full 1448 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.